 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 The authors concluded that the trial "shows that low-dose dexamethasone in conjunction with lenalidomide is an active regimen for newly diagnosed myeloma with acceptable toxicity and low early mortality."
They also noted that "the use of high-dose dexamethasone is not needed for the most part in the context of new active agents for myeloma, and as a result almost all current phase 3 trials have adopted low-dose dexamethasone as the standard in combination regimens."
The study was published online Oct. 21 in The Lancet Oncology.
Text Continues Below
More information
The American Cancer Society has more about multiple myeloma.
Page: << Prev | 1 | 2
-- Robert Preidt
|
.gif)
